While our data demonstrate a strong negative correlation between USP22 and β2M across multiple human cancer types, we were only able to recruit 32 patients with lung cancer to assess the predictive value of USP22 expression for anti–PD-1 ICB responsiveness. This evidence concerns the gene USP22 and lung carcinoma.